Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Future Proof Brands, maker of the popular ready-to-drink brand BeatBox, is laying off over 150 employees at its headquarters. The move comes weeks after announcing a $490 million majority stake acquisition by Anheuser-Busch, signaling corporate restructuring ahead of the deal's expected close in early 2026.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
First Bank Corp. has entered into a definitive agreement to merge with Russellville-based First State Bank, a strategic move set to deepen the holding company's roots in the Arkansas River Valley region while preserving the community bank's local identity.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
The Producer Price Index jumped 0.5% last month, more than double November's increase, as rising costs for machinery, metals, and travel services pointed to persistent pipeline pressures for consumers.
Despite a bruising year, XRP's legal clarity, banking ambitions, and technical upgrades position it as a speculative recovery play for investors eyeing the next market cycle.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
Soybean prices extended their decline on Friday, pressured by lackluster export sales data and a broader commodity sell-off. With key commitments lagging last year's pace, traders are now looking ahead to next week's crush data for signs of domestic demand strength.
Bitcoin's rally to near $91,000 this week was abruptly halted as the U.S. dollar found its footing. The shift highlights the cryptocurrency's growing sensitivity to traditional macroeconomic forces and Federal Reserve policy speculation.
A dramatic reversal in precious metals markets saw silver crash 35% and gold fall 12% in a single session, testing a long-held crypto theory about capital rotation as Bitcoin demonstrates relative stability.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
For long-term investors, volatility presents both opportunity and peril. We examine one stock with explosive potential and two others where caution may be warranted amid shifting market dynamics.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
The $10 to $50 per share range is a hunting ground for investors seeking established, mid-sized companies with growth potential. While often less volatile than penny stocks, they are not without risk. We analyze one stock with promising upside and two facing significant headwinds.
While the consumer staples sector has lagged the broader market rally, select companies continue to demonstrate defensive strength and growth potential. We analyze one standout and two stocks facing significant headwinds.